9966 — Alphamab Oncology Share News
0.000.00%
Last trade - 00:00- HK$5.54bn
- HK$4.18bn
- CNY566.24m
Brief: Alphamab Oncology Receives Approval From CDE China For JSKN003 To Initiate Phase III Clinical Study
Brief: Alphamab Oncology Resolved To Repurchase Ordinary Shares Up To HK$50 Mln In Value
China's Alphamab Oncology tanks on phase III trial results
HK-listed Alphamab Oncology jumps most in 3 months on licence agreement
Brief: Alphamab Oncology Says License Agreement With 3D Medicines And Glenmark
Brief: Alphamab Oncology Says Phase I/II Clinical Trial Of JSKN033 Approved In Australia
Brief: Alphamab Oncology Says Aware Of Certain Media Reports
China's Alphamab Oncology falls third straight session to a year-low
China's Alphamab Oncology climbs on progress of new drug development
Brief: Alphamab Oncology Posts HY Loss RMB39.9 Million
Brief: Alphamab Oncology Says Loss For Year RMB325.7 Million
Brief: GIC Private Ltd's Long Position In Ordinary Shares Of Alphamab Oncology Falls To 4.96% - Filing
China's Alphamab Oncology falls on discounted share sale
Brief: Alphamab Oncology Says Got IND Approval From National Medical Products Administration Of China
Brief: Alphamab Oncology Posts HY Loss For Period RMB147.3 Million
Brief: Alphamab Oncology Posts Loss For Year Rmb412.4 Million
Brief: Alphamab Oncology Says IND Approvals By China's Nmpa For A Phase Ia/Ib Clinical Trial- Of Kn052 In Treatment Of Advanced Solid
Brief: Alphamab Oncology Announces KN035 (Envafolimab) Obtained Marketing Approval In China From NMPA
Brief: Alphamab Oncology Got Investigational New Drug Approval By Nmpa For A Phase III Clinical Trial Of KN046